The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I'm a trader and I watch this share and contribute occasionally, I've found that 40 tends to be the bottom but right now this feels an incredible entry point as it doesn't drop to 40 that often. News on a deal or update on the business tends to boost the sp to mid 50-60 area so a good 20-30% profit depending on how low you get it.
I think it will stay this way until the business is starts making profits and shows consistent sales by which point the sp will be way higher
Barder has a real skill at killing off the SP no matter what he says!!
My view is that it has become a traders share albeit that the traders sell at a loss!
I think the fact that FUM do not anticipate making a profit until 2024 has been a fundamental driver in the latest sell off.Although it should be noted that the volume of trades is relatively low.
The cautious attitude of Barder does not help.
The other factor that has had a negative effect on the share price is the opaque nature of the last RNS.Can any one articulate what profit they are making per sale?
The latest selling will burn itself out and as I have stated before the price will then drift higher probably only to go through the same cycle again and again.
It's typical for shares to drift lower after news, but they soon get snapped up if it drifts too far! plenty of news about new country distribution agreements are going to be in the pipe line for a while, hope this doesn't turn into a traders share
“With further commercial agreements and product launches planned through the remainder of 2023 and beyond, Futura is well positioned to continue on its growth trajectory, bringing a new OTC ED breakthrough treatment to sufferers globally”.
Bring it on, let’s have some news!
Darky, it is in this interviewhttps://ca.finance.yahoo.com/news/futura-medical-track-profit-2025-152030201.html may also be mentioned elsewhere,but i haven't checked.
Petit
Interesting write up.
I try to join up the dots whilst closely reading Rns and video/webcasts.
A few observations to offer debate on ref some points if I may?
A few. people have stated this also.
May I ask?
I don't believe I have seen specific mentiion of a 200000 plus figure of sales of eroxon in Q2?
Only a £1.7m sales with £900000 net profit in that period?
Have I missed that specific reference?
Regards
Darky
Haleon, the world's leading consumer healthcare company is going to take this out. Will not remain and independent for long. Lovely fit for Haleon with all their other products. £1.00 and above easy.
Insummary ....we are all awaiting drop of the penny in the city. SP propulsion should follow.
I have long said, and beleived, that FUM requires a more dynamic and city friendly house broker to expidite this.
However, watching the SP movement daily is not the way to go. Those who have connected the dots will be comfortable.
Absolutely Pet, I and I'm sure most of the other investors in FUM would agree with you. Do you think James reads this board? I would if I were him but if not maybe you could pass your message onto him directly.
The trajectory its bright prospects deserve.
The dream customer for any business says nothing and does nothing. Underperforming managers of plcs love non-activist shareholders, but know there’s always the threat of takeover, or of an activist investor shaking up company management to improve company performance.
In my opinion, Futura’s current executive has delivered operationally, albeit hampered by the time lags (and costs) created by (1) the FDA and (2) their licensing partners bringing Eroxon to market.
But I do wonder whether it’s not time to bring in an investor relations specialist focused on marketing Futura to investment managers. James Barder has his strengths, but stepping up to the communications plate to ‘sell’ the Futura story through 3 presentations (interims, Proactive Investors, investor meet) of the same slides / information to the same audience clearly isn’t changing the mood music for the share price. Einstein said “ The definition of insanity is doing the same thing over and over again, but expecting different results”.
James can’t rely on investors ‘joining the dots’ in terms of the 200,000 units, or of anything else. After all, you can be sure as eggs are eggs that if Futura publishes any new information, that information is immediately misinterpreted and misrepresented by some investors, and overlooked by others - not necessarily deliberately, but through laziness, or a simple inability to process information accurately. As we see time and again on this board, the ‘arc of distortion’ among some investors is big indeed. So he needs to use his results presentations to be more visionary in terms of the metrics that matter for the share price: revenue and profit growth, presenting not discrete slides but ones that tell a coherent, flowing and embracing story. For example, he really didn’t highlight and follow through the implications of the 200,000 units sold in Q2.
Contrast his skating over this with his probable use of the same information if Futura was having an IPO or fending off a takeover approach at, say, £1. No doubt he’d be showing forecasts with big annual increases in revenue and profit, subject to partners’ roll out plans. Investors would want to buy in to the company or hold onto their shares, rather than chopping another 10% off the company’s market value.
Keynes stated that “In the long run we are all dead”. No current long term investor has an indefinite time in the stock. We will all eventually sell or die. Brokers have current price targets excluding sales that are north of £1. Some of us would like the current share price to reflect these (conservative) targets, so that we can enjoy the fruits of our investment now. But instead Futura’s current share price more resembles a heavy discount investment trust than a fast growing tech company.
James could consider employing an investment specialist whose focus is selling Futura’s story to institutions, to move the company’s share price onto
Yes, a market cap of £141m, does not look too big when you consider eroxon will eventually be sold world wide.
If we just look at the value of FUM £150m, based on the current sales of around £1m per month £12m a year for UK & Belgium! We maybe a little over priced! But as many have said logically as we add more territories to the sales figures the SP will rise, we will get the sudden rise once the market realises it’s not a Fad & the money keeps rolling in. Let’s not forget we also have other products that are on hold currently that will add to the value long term. So hold steady LTH we will find the good at the end of the rainbow soon.
And led by LiarBOoth, no doubt!
My opinion is there is a group shorting this and they are convening over the weekend at sharestock or whatever its called.
They are the same people that have been posted multiple fake reviews
I am a little befuddled about PI's obsession regarding the state of current SP.
Of course, it would be of absolute importance, if one was trading it.
However, self confessed LTH,s showing imminent concern relating to SP is a little bewildering. Just focus on all the company positives. The short term SP is of no real consequence as long as the key fundamentals of the company remain positive. (There is no real substance for marking down of the SP). The market reads trends and makes judgement. Here, it's too early for trends so just accept the erratic SP, for now, and wait for further launches.
Yup they are sure picking up a bargain with this continued fire sale.
Hopefully some big investor building up a holding, clearly too many shares for MM’s the manipulate SP with currently.
MMs are pushing out small holders in favour of large holders I expect an Rns or two any day. Observe carefully and you will see large trades quietly going through every day
50% profit is not too shabby!!!!
$4 million
Haleon would of done there due diligence before handing over $4 upfront payment for the right to market eroxon in the US, there's a lot of advertising spend as well.
To Be fair Toli, if you invest in this share you DO look at the share price and as mentioned previously when this got approved in the U.S. all of us thought this would pick up. It hasn't. It appears that the company is at long last making money and Erexon is getting listed around the world. We even had a spate of good publicity but still the S.P. has resisted a move in a positive direction. The company needs to shout louder and put Marketing and P.R into overdrive.